Outcome of men presenting with clinical breast problems: the role of mammography and ultrasound

The purpose of this study was to determine the outcome of men presenting with clinical breast problems for breast imaging and to evaluate the role of mammography and ultrasound in the diagnosis of benign and malignant breast problems. We retrospectively reviewed clinical, radiographic, and pathologic records of 165 consecutive symptomatic men presenting to Breast Imaging over a 4 year period. We assessed the clinical indication for referral, mammographic findings, sonographic findings, histologic results, and clinical outcomes. Patients ranged in age from 22 to 96 years. Breast Imaging Reporting and Data System (BI-RADS) category 4 and 5 mammograms and solid sonographic masses were considered suspicious for malignancy. Six of 165 men (4%) had primary breast carcinoma, which were mammographically suspicious in all 6 (100%). Five were invasive ductal carcinoma and one was ductal carcinoma in situ (DCIS). Of 164 mammograms, 20 (12%) were suspicious. Six were cancer and 14 were benign. Clinical follow-up for 2 years or biopsy results were available for 138 of the 165 men (84%). Twelve with benign mammographic findings had benign biopsies. All men with benign mammography not undergoing biopsy were cancer free. Sensitivity for cancer detection (mammography) was 100% and specificity was 90%. Positive predictive value (mammography) was 32% (6 of 19) and the negative predictive value was 100%. Sonography was performed in 68 of the 165 men (41%). Three of three cancers (100%) were solid sonographic masses. There were 9 of 68 false-positive examinations (13%). Sensitivity and negative predictive value for cancer detection (ultrasound) was 100% and specificity was 74%. The most common clinical indication for referral was mass/thickening (56%). Mammography had excellent sensitivity and specificity for breast cancer detection and should be included as the initial imaging examination of men with clinical breast problems. The negative predictive value of 100% for mammography suggests that mammograms read as normal or negative need no further examination if the clinical findings are not suspicious. A normal ultrasound in these men confirms the negative predictive value of a normal mammogram.     

The dangers of mammography in diagnosing a palpable lump in the breast

The success of mammography screening programmes in the detection of unsuspected and impalpable breast cancer has led to reliance on a negative mammographic report as assurance that no malignancy is present even in palpable breast lumps. Pre-operative mammography was performed on 38 patients with palpable lumps who were subsequently proven by histology to have carcinoma of the breast. In 4 patients (10.8%) the mammogram was negative; 3 were also assessed as benign clinically. In 5 cases (13.5%) the report was negative but biopsy was recommended; 3 of the 5 were assessed as benign clinically. Therefore, in 9 of the 38 patients (24%) malignancy was not diagnosed unequivocally on mammography, although 3 of these patients had clinical stigmata of malignancy. Twenty-nine patients (76%) were diagnosed correctly by mammography; 5 of these cases were assessed as benign clinically. Six of the 38 cases (16%) were thought to be benign on both mammography and clinical examination. Thus, even confirmation by mammography that a breast lump without clinical signs of malignancy is indeed benign, does not rule out the possibility of carcinoma.     

Comparative Value of Mammography,Fine-Needle Aspiration Biopsy,and Core Biopsy in the Diagnosis of Invasive Lobular Carcinoma

Abstract: Invasive lobular carcinoma of the breast (ILC) is a lesion often cited as being more difficult to diagnose than invasive ductal carcinoma. Our objective was to assess the role of mammography, fine-needle aspiration biopsy (FNAB) and large core needle biopsy (LCNB) in the diagnosis of invasive lobular carcinoma of the breast. We reviewed 1,074 consecutive patients with invasive cancers of the breast, of which 102 (9%) were ILC. All the patients with ILC had mammography, 66 had FNAB, and 15 had LCNB performed. Of the patients with ILC, 95 of 102 (93%) had an abnormal mammogram. Seven patients (7%) had a negative mammogram. The most common radiographic finding in patients with ILC was a spiculated mass (42%). The average size of the cancers detected by mammography was 1.17 cm, with no significant effect of size on the ability to detect cancer based on its mammographic presentation for p > .05. Sixty-six patients had FNAB, with a postive diagnosis of cancer in 27 (41%) and suspicious or atypical aspiration in 20 patients (30%). Nineteen patients (28%) had false-negative aspirates. There was no significant difference in size for patients whose cytology demonstrated malignant, suspicious, atypical, or benign aspirates, F (4,56) = 1.01, p > .05. For the fifteen patients who had LCNB, a definitive diagnosis of ILC was made in 13 cases (87%), with another patient having a diagnosis that was “suspicious” for ILC. One patient had a false-negative LCNB. ILC can be detected by mammography, in most instances. FNAB may fail to diagnose this cancer, particularly if the cancer is of low nuclear grade. The lack of reliability of FNAB for diagnosis of ILC, which may occur in some cases is due to the discontinuous infiltrative pattern and the intrinsic cytologic characteristics of this cancer. LCNB is a complementary diagnostic procedure when the FNAB is nondiagnostic to demonstrate the presence of ILC. In the presence of a dominant mass by palpation and a clinical suspicion of the presence of ILC, a negative mammography or a benign FNA should not preclude a surgical biopsy.     

Diagnosis of breast cancer in young women

While the prognosis of younger women with breast cancer is controversial, there have been several significant reports indicating a more unfavourable outcome of the disease in this age group. A review has been conducted of the problems encountered in the diagnosis of breast cancer in younger women. The records of 227 consecutive patients aged 30-40 years who underwent breast biopsy were retrospectively analysed, and data studied in relation to the proportion of malignant to benign biopsies, the clinical and pathological features of the malignant cases, and the method of diagnosis. A total of 235 biopsies was performed in 227 patients, of which 199 were benign (85%) and 36 were malignant (15%), giving a malignant to benign biopsy ratio of 1:5.5. Thirty-six cancers were diagnosed in 35 patients. Among these young women with breast cancer, the average duration of symptoms was 26 weeks, the mean clinical cancer diameter was 3.3 cm and only a small proportion (28%) of women had early (Stage I) disease. There were 4 women with breast cancer (11%), in whom the diagnosis of malignancy was unsuspected preoperatively. Mammography in these younger women appears to have a more limited role, with a sensitivity of only 76%. These findings indicate that the diagnosis of breast cancer in younger women is often more difficult than in older age groups and that the presentation and detection of such cancers is often delayed. Younger women need to be educated in relation to seeking early medical review of breast lumps and clinicians need to be aware of the limitations of mammography in such cases.     

The utility of breast MRI as a problem-solving tool

Breast magnetic resonance imaging (MRI) is routinely used as a problem-solving tool, but its benefit for this indication remains unclear. The records of 3001 consecutive breast MR examinations between January 1, 2003 and June 6, 2007 were reviewed to identify all those performed for the clinical indication of problem solving. Details of clinical presentation, mammography and ultrasound (US) findings, follow-up recommendations, and pathology outcomes were recorded. Benign versus malignant outcomes were determined by biopsy or 12 months of follow-up imaging and linkage with the regional tumor registry. Problem solving was the clinical indication for 204 of 3001 (7%) of all examinations. Forty-two of 204 examinations (21%) had suspicious or highly suspicious MRI assessments with recommendation for biopsy and 62 of 204 (79%) examinations were assessed as negative, benign, or probably benign. Thirty-six biopsies were performed based on MRI findings and 14 cancers were diagnosed. Biopsy was indicated for 11 of 14 (79%) cancers based on suspicious mammographic or US findings identified prior to MRI. One incidental cancer was detected by MRI alone in a patient at high risk for breast cancer, and two cancers were detected in patients with suspicious nipple discharge and negative mammogram and US. A single false-negative MRI occurred in a patient whose evaluation for a palpable lump prompted biopsy. Problem-solving breast MRI rarely identifies otherwise occult cancer and can be falsely negative in patients with suspicious findings on mammogram and US. Until the benefits and risks of problem-solving MRI are clarified, it should be used judiciously.     

Follow-up recommendations for benign breast biopsies

Histologically proven benign breast disease increases a woman's relative risk for subsequent cancer development. Yet follow-up guidelines for mammogram and clinical breast examination after a benign breast biopsy are lacking. Our objective was to determine if increased surveillance is indicated following a benign breast biopsy. Following institutional review board approval, a retrospective database review was conducted of prospectively gathered patients who had a benign breast biopsy (core or excisional) for an abnormality detected on mammogram, ultrasound, or clinical breast examination. Follow-up, for all subjects, was a clinical breast examination and mammogram or ultrasound at 6 months, 1 year, and 2 years after benign breast biopsy by a breast surgeon. End points were the need for additional biopsies or cancer detection. Statistical analysis was performed using chi-squared analysis. From January 2000 to July 2003, 156 patients age 18-86 years had a benign breast biopsy. During the 2 year follow-up, 20 patients (13%) required a subsequent biopsy. No significant difference was observed in mean age, race, menarche, menopause, parity, age at first live birth, use of oral contraceptives, history of prior biopsy, or the pathology of the initial lesion between those who needed a subsequent biopsy and those who did not. Seven excisional biopsies were performed (one at 6 months, four at 1 year, and two at 2 years follow-up) for growth of the benign breast biopsy lesion, and pathology remained concordant with the original diagnosis. Thirteen biopsies were done for new findings on mammogram or ultrasound. Three of these (1.9%) yielded a cancer diagnosis (one at 6 months, one at 1 year, and one at 2 years follow-up). No new lesions were identified on follow-up by clinical breast examination alone. Increased surveillance following a benign breast biopsy is necessary because of the increased need for subsequent biopsy or risk of cancer development. This should include imaging (mammography or ultrasound) and a clinical breast examination 6 months, 1 year, and 2 years after a benign breast biopsy.     

SiteSelect: minimally invasive excision of breast lesions

The goal of screening mammograms is to provide early detection of breast cancer. As mammography technology improves, the ability to detect smaller and smaller suspicious lesions is increased. However, as mammography cannot always differentiate between malignant and benign lesions, biopsies are often needed. With the decreasing size of lesions seen on mammography, the size of the biopsy specimen needed for diagnosis also decreases. Thus, a smaller amount of normal breast tissue needs to be removed during a biopsy. For a majority of the small lesions, excision with a small margin of normal breast tissue is sufficient for diagnosis. The SiteSelect procedure utilizes stereotactic guidance to excise completely a tumor that is noted on a mammogram. The procedure can be performed under local anesthesia through a minimal incision (usually 1.5 cm). The SiteSelect™ biopsy procedure completely excises small tumors noted on the mammogram with minimal trauma to the breast tissue and with excellent cosmetic results. It is well tolerated by patients. For tumors requiring only local excision, such as atypical ductal hyperplasia or lobular carcinoma in situ, the SiteSelect procedure may be the only diagnostic procedure required.     

Productivity of needle localization to facilitate excision of nonpalpable, mammographically suspicious lesions

The use of needle localization to aid excisional biopsy of nonpalpable breast lesions is now common, and the literature suggests that 13% to 33% of such lesions are malignant. During the 4 years from 1984 to 1988, all women who underwent fine-needle localization in preparation for biopsy were studied to identify factors that might facilitate the selection of those more likely to harbour a cancer, thus sparing patients with benign disease operative intervention. In all, 124 biopsies were performed on nonpalpable lesions that were suspicious on mammography; 51 lesions were malignant and 73 benign. The average age of the patients was 56 years (55 years for those with benign lesions and 61 for those with malignant lesions). The family history, history of breast disease, symptoms and calcification seen on mammography were not significantly different between the two groups. Only 25% of the malignant lesions were noninvasive. In 10% of the patients who had invasive lesions there was lymph-node involvement. The rate of malignancy in this patient population (41%) was slightly better than that reported in the literature, and a larger proportion of patients had noninvasive disease. The authors conclude that none of the above-mentioned risk factors could be used in the preoperative selection of patients for open biopsy.     

Ultrasound-Guided Fine Needle Aspiration Biopsy Update 1998

Abstract: Breast ultrasound using a high-resolution, realtime, hand-held probe was performed on 19, 714 patients. Ultrasound-guided fine needle aspiration biopsy was done on 2,453 solid masses. We report on 2,075 of these lesions, 629 malignant and 1,446 benign, confirmed either by excisional biopsy or adequate follow-up. Of the cancers, 597 (95%) had either malignant or suspicious cytology with 1 false positive case and 32 false negative cytologic results. The diagnosis of cancer was delayed in four patients because of benign appearances on imaging and cytology. Surgery was performed promptly after the first imaging follow-up in each case. There was no delay in diagnosis in the remaining 11 patients because of the suspicious appearance of the masses on mammogram. Mammography missed 147 (23%) of the 629 cancers, 102 of which were clinically palpable. Forty-five cancers were both nonpalpable and not seen by mammogram (incidental cancers). A correct cytologic diagnosis, either fibroadenoma or nonspecific benign, was made in 1,339 of the 1,446 benign masses. The sensitivity of this technique in the diagnosis of solid breast lesions was 95%, the specificity was 93%, and the overall accuracy was 93%. We conclude that real-time, ultra sound-guided fine needle aspiration cytology is a valuable adjunct to the clinical, mammographic, and sonographic assessment of solid breast lesions.     

Normal mammography and ultrasonography in the setting of palpable breast cancer

BACKGROUND: Each year thousands of women present to general surgeons with palpable breast masses, some of which are clinically ambiguous and the majority of which are benign. In addition, surgeons are frequently faced with the question of whether to biopsy those palpable abnormalities in the setting of normal radiographic studies. One might propose that such lesions could be safely observed rather than immediately biopsied. If these lesions were not biopsied, how many cancers would escape detection? To address this issue, a population of patients with known, palpable breast cancer was retrospectively examined to determine the frequency of normal or benign findings on both mammography and ultrasonography. METHODS: Between January 1998 and December 2001, 351 women with breast carcinoma presented initially with palpable tumors. The medical records of these remaining 351 cases were retrospectively reviewed to examine the radiographic characteristics of the palpable carcinomas. RESULTS: Of the 351 cases in the study group, 13 (3.7%) patients with palpable breast cancers had mammogram and sonogram examinations that were both normal, benign, or nonspecific in appearance. CONCLUSIONS: The results of this study indicate that nearly 4% of women with breast cancer who present with palpable lumps will have normal or benign findings on both mammography and ultrasonography. These data support prior studies of similar false negative rates and may provide some reassurance to surgeons and patients regarding clinical breast lumps, as the decision of whether to biopsy still rests in the surgeon's hands. However, inappropriate reliance on these tests for an evaluation of a palpable abnormality will result in a number of missed tumors.     

Benign breast disease in a West Indian population

A review of 1726 breast lesions in West Indian women from Trinidad showed that the pattern of disease is significantly different from that reported in whites but similar to reports from India and Africa. This difference is mainly due to the high frequency of fibro-adenoma in our adolescent women. Fibro-adenoma was the commonest lesion (39.3 per cent), followed by mammary dysplasia (32 per cent) and carcinoma (21 per cent). Although carcinoma comprised only 21 per cent of all breast lesions, nearly 40 per cent of true neoplasms were malignant. We believe all suspicious breast lumps in black women need biopsy and further analysis of morphological components of benign breast lesions is necessary to evaluate precursors to cancer of the breast.     

Utility of short-interval follow-up mammography after a benign-concordant stereotactic breast biopsy result

BackgroundThere is currently no clear consensus recommendation for the use of short-interval follow-up mammography after a benign-concordant breast biopsy (BCBB), and practice patterns vary widely. The objectives of this study were to evaluate whether a short-interval follow-up mammogram provided clinical utility after stereotactic BCBB and to examine the costs associated with this surveillance strategy.MethodsA retrospective review of women who underwent a stereotactic breast biopsy yielding benign-concordant results between January 2005 and October 2014 was performed to evaluate findings on subsequent imaging, to calculate compliance with recommended short-interval imaging, and to examine whether subsequent imaging revealed an abnormality at the site of the initial stereotactic BCBB. A cost analysis was performed utilizing Medicare reimbursement rates to calculate projected and actual costs of short-interval follow-up imaging after stereotactic BCBB.ResultsOf the 470 stereotactic BCBB performed, a short-interval mammogram was completed in 207 (44.0%), 9 (4.3%) of which had suspicious mammographic findings at the initial biopsy site, and 6 subsequently underwent biopsy, with none resulting in malignant or high-risk pathology. The cost of short-interval mammographic follow-up (n = 207) was calculated at $28,541.16.ConclusionsThis study provides evidence that 6-month follow-up mammography has low clinical utility and unnecessarily increases costs after stereotactic BCBB. A safe and more cost-effective strategy may be resumption of routine mammography at 12 months post-biopsy.     

Which breast to biopsy: an expanding dilemma.

To provide insight into the significance of findings reported from screening asymptomatic women for breast cancer, we reviewed 19,928 mammographic studies with the accompanying physical examination and correlated these findings with 554 breast biopsies. Of 83 breast biopsies with suspicious findings on both physical examination and mammography, 72 demonstrated breast cancer (87%). Of 155 biopsies for suspicious changes on mammography alone, 50 (32%) demonstrated breast cancer. The accuracy of suspicious mammography was independent of findings limited to physical examination, 34 (17%) had breast cancer; 31 were in 152 biopsies of patients with mammography interpreted as normal (20%) and three were in biopsies of 52 patients (6%) in whom a visualized mass was interpreted as benign. One hundred and twelve breast biopsies were performed for changes interpreted as normal or benign. Six malignancies were discovered (5%). No cancer was found in 31 biopsies for nonpalpable benign mammographic abnormalities. Our results emphasize the importance of discriminating between nonvisualization of a mass and mammographic recognition of either a benign or malignant tumor. The reliability of interpretation is considerably greater for a visualized lesion than a nonvisualized one.     

Predicting Biopsy Outcome After Mammography: What Is the Likelihood the Patient Has Invasive or In Situ Breast Cancer?

Background As many as 1,000,000 breast biopsies are performed annually in the United States. Although substantial effort has been devoted to estimating breast cancer risk, there have been no studies to predict outcome in women undergoing breast biopsy.Methods A population-based study was undertaken to develop and test models for predicting the probability of invasive breast cancer and/or ductal carcinoma-in-situ in 7670 women undergoing breast biopsy after mammography. Logistical prediction models were developed by using data from 6129 randomly selected women and tested with data from the remaining women.Results The overall cancer prevalence among women undergoing biopsy was 22.4%. Prevalence in women with mammograms highly suggestive of malignancy (category 5) was 84.6%, with minimal variation in individual cancer probabilities due to age. A total of 24.6% of women with suspicious mammograms (category 4) had cancer, but individual probability estimates ranged from .01 to .86, depending on age, presence of a lump, previous biopsy, menopausal status, and use of postmenopausal hormone therapy. These variables also influenced biopsy outcome in women with other mammography assessments (categories 0–3), but the overall prevalence was lower (8.6%), and estimated probabilities ranged from .01 to .45. When cancer was present, the probability of invasive disease was influenced by mammogram assessment category, absence of mammogram calcifications, and presence of a lump.Conclusions The probabilities of invasive cancer and ductal carcinoma-in-situ in women undergoing biopsy can be more accurately predicted by using clinical characteristics in addition to mammography findings. This information could potentially influence decisions regarding immediate biopsy or continued surveillance.The views expressed in this article are solely those of the authors and do not necessarily represent the official views of the National Cancer Institute or the Federal government.     

��ͬ�ٴ���Ӱ��ѧ��������������ͷ��Һ����������ϼ�ֵ����

??Value analysis of different clinical and imaging features in the diagnosis of benign and malignant nipple discharge HUANG Jia-hui??CHEN Xiao-song, WU Jia-yi, et al. Comprehensive Breast Health Center, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai 200025, China
Corresponding author: SHEN Kun-wei, E-mail: kwshen@medmail.com.cn
Abstract Objective To analyze the value of different clinical and imaging features in the diagnosis of benign and malignant nipple discharge. Methods The clinical data of 233 patients treated with surgery for nipple discharge from January 2011 to February 2016 in Ruijin Hospital Affiliated to Shanghai Jiao Tong University School of Medicine were analyzed retrospectively. A total of 233 cases without palpable mass were enrolled in the analysis. Thirty-three patients (14.2%) were diagnosed as breast cancer, and the other 200 patients (85.8%) were diagnosed as benign disease. The sensitivity, specificity, negative predictive value (NPV), and positive predictive value (PPV) of mammogram, ultrasound, MRI and their combination in predicting malignant disease were calculated. Results Patients with bloody nipple discharge (P=0.008), with suspicious calcification on mammography (P<0.001)??with segmental enhancement (P=0.003) or with washout-pattern kinetic curve (P=0.023) on MRI had higher risk of breast cancer. The sensitivity of mammography in diagnosing breast cancer was 57.6%, significantly lower than that of ultrasound (87.9%,P=0.012) and MRI (93.9%??P=0.001). The sensitivity of mammography combined with ultrasound or with MRI was 90.9% and 100% respectively, significantly higher than that of mammography alone (P=0.004, P<0.001) .Conclusion Bloody nipple discharge, with suspicious calcification on mammography, with segmental or with washout-pattern kinetic curve on MRI are risk factors for predicting breast cancer in patients with nipple discharge without palpable disease. The sensitivity of breast cancer can be elevated with ultrasound or MRI comparing with mammography alone.     

Retrospective evaluation of surgically treated cases of non-palpable breast tumor

Between 10.01.1997 and 09.30.1999 authors performed operations on 78 patients who had nonpalpable breast tumors. If mammography was considered abnormal during breast screening program patients were recalled. Besides clinical investigation complimentary mammograms were performed. After sonogram, and if needed, aspiration biopsy cytology (ABC) if necessary core biopsy (CB) was the next investigation. 79 operations were performed on 78 patients (one was patient had synchronous breast tumor). The mean age of the patients was 56.3 years. If the radiological investigations (R4-R5) and/or the ABC (C4-C5) or CB suggested malignancy operation was performed. Mammography suggested malignancy in 60.75% of the patients, it was suggested by ABC in 30.18%, and by CB in 55.5%. The nonpalpable tumor, suspected to be malignant was marked with a wire loop and was excised under anesthesia along with the affected breast sector. The excision and tissue-border around the tumor was checked by specimen mammography performed during the narcosis. No cryohistology was performed. After the specimen mammography, the wound was closed. The final histology of the operations showed malignancy in 40.5%. In their retrospective study the authors evaluated the complete sensitivity and the positive predictive value (PPV) of the preoperative investigations regarding the final histology. They analyse the value of preoperative mammogram, the ABC and CB in malignant and in benign cases. Early diagnosis and surgical treatment is expected to improve significantly the survival of patients with breast cancer. Reduction in the number of unnecessary operations can be expected from increasing the accuracy of radiological and cytological investigations and the adequate usage of core biopsy.     

Accuracy of combined clinical-mammographic-cytologic diagnosis of dominant breast masses. A prospective study

Excisional biopsy is considered a mandatory part of the workup for patients with dominant breast masses. To evaluate the efficacy of a combined physical, mammographic, and fine-needle aspiration cytologic examination, 113 women were prospectively evaluated. Breast masses were listed as either benign or suspicious/malignant. All patients underwent a subsequent biopsy. Fifty-two (46%) of 113 patients had a malignant mass. The sensitivity and specificity of the individual tests were as follows: 96% and 66% for the physical examination; 94% and 73% for the mammographic examination; 90% and 93% for the fine-needle aspiration cytologic examination. For the 86 patients who underwent all three studies, the 25 patients with benign test results on all three examinations had a benign pathologic result. One (6%) of 18 patients with a single suspicious/malignant test result had cancer, 9 (64%) of 14 patients with two suspicious/malignant test results and 28 (97%) of 29 patients with three suspicious/malignant results also had breast cancer. We conclude that the combined triad of physical, mammographic, and fine-needle aspiration cytologic examinations is highly accurate in the diagnosis of breast masses, and patients in whom all three examination results are benign can be safely observed, obviating the need for an open biopsy.     

Negative predictive value of sonography and mammography in patients with focal breast pain

The purpose of this study was to determine the negative predictive value of mammography and sonography in a population of patients with focal breast pain referred for imaging evaluation. Eighty-six consecutive patients with focal breast pain in the absence of a breast mass were retrospectively identified from an imaging database. The electronic inpatient and outpatient records for the 86 patients were reviewed. For patients who were diagnosed with breast cancer, pathology reports were reviewed to determine whether the painful area corresponded to the patient's cancer. In addition, patient records were linked to the institution's cancer registry. Of the 86 patients, 26 patients were lost to follow-up and did not appear in the institution's cancer registry. Four patients were diagnosed with breast carcinoma, two of whom had incidental cancers that were detected mammographically by microcalcifications and were separate from and unrelated to the area of pain. Seven patients underwent biopsy at the site of breast pain with benign diagnosis. Imaging and clinical follow-up for the 51 patients with benign or negative imaging at the site of pain showed no abnormality with a mean follow-up of 26.5 months. The negative predictive value of mammography and sonography in patients with breast pain was 100%. The negative predictive value of mammography and sonography for focal breast pain is high. Negative mammography and sonography can be reassuring to the treating clinician if follow-up is planned when physical examination is not suspicious. However, if physical examination is suspicious, biopsy should not be delayed.     

Triple assessment of breast lump

Objective: To determine the sensitivity, specificity, positive and negative predictive values of triple test (TT) consisting of physical examination (PE), mammography, fine needle aspiration cytology (FNAC) in the evaluation and characterization of palpable breast lump. Secondly, whether this can be employed as an alternative for tru cut/ excisional biopsy. Study Design: Cross-sectional study. Place and Duration of Study: This study was conducted in the department of diagnostic imaging, Shifa International Hospital (SIH), Islamabad in collaboration with departments of surgery and pathology from January 2004 to June 2005. Patients and Methods: It comprised of 35 consecutive females presenting in the breast clinic with palpable lump. Females below 35 years of age were excluded due to low sensitivity of the mammography in depiction of focal breast lesions resulting from glandular parenchyma. Patients with acute inflammatory signs, fungating masses, pregnant ladies as well as those with cystic lesions, as confirmed by ultrasound, were also excluded from the study. Number, size and recurrent masses did not influence the inclusion criterion. Detailed history and physical examination was carried out as per established protocol. It was followed by mammography and FNAC. All cases underwent excisional biopsy irrespective of the results of the triple test. Results: The patients' age ranged from 35 to 75 years with mean age of 45.97. Amongst these, 19 cases were benign (54.28 %) and 16 cases (45.71 %) were malignant. The triple test (TT) was scored as concordant if the elements had either all malignant or all benign results. The triple test was non-concordant if the elements had neither all malignant nor all benign results. The TT was concordant in 19 cases (54.28 %) i.e all the benign cases detected by the triple test were benign on final biopsy (100 % specificity and NPV), all the malignant lesions detected by TT turned out to be malignant on final biopsy (100 % sensitivity and PPV). Triple test was non-concordant in 16 cases (45.71 %). Triple Test was scored as benign or malignant based upon the combined results of two elements amongst three components. Out of these, 11 cases were malignant and 5 were benign. In 4 cases, the components of the triple test were suspicious i.e. BIRAD IV on mammography and slight atypical cells without frank malignancy on FNAC. In current study, suspicious cases were taken as malignant. These turned out to be malignant at the end signifying 100% PPV. However, among the 12 cases where, at least one of the 3 components of TT was benign, FNAC was most accurate (2 False Negative (FN) and 0 False Positive (FP), followed by mammography (2 FN and 3 FP) and physical examination was least accurate with 3 FN and 4 FP. It is of note that in 2 cases where FNAC gave FN results, the other two components were either suspicious or malignant. In those cases where two variables were malignant, FNAC and mammography were most accurate with no false positive or false negative. It was followed by physical examination and FNAC with 1 false negative and no false positive. Conclusion: The study shows that when TT is concordant, final treatment may be ensued without open biopsy. In non-concordant cases, FNAC stands as single most important investigation. However due to its false negative results, other components of triple test need to be employed to enhance its efficacy and diagnostic yield. TT is cost effective, easy to perform and time saving approach, however, it can be applied only in those institutions where excellent imaging facilities as well as services of a cytopathologist are available. Due to small sample size, the results of this study needs further verification by relatively larger scale studies.